J. Goldman & CO LP Krystal Biotech, Inc. Put Options Transaction History
J. Goldman & CO LP
- $2.89 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding KRYS
# of Institutions
262Shares Held
21.5MCall Options Held
462KPut Options Held
723K-
Avoro Capital Advisors LLC New York, NY2.56MShares$454 Million5.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$432 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$321 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.51MShares$268 Million10.58% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$176 Million9.23% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.56B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...